Related Experiment Video
Updated: Oct 3, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
Toward the Use of Real-World Data for Regulatory and HTA Decision-Making: Experiences and Recommendations from Six
Martin Russek1, Jonas Peltner1, Kerstin Pfeifer1
1Research Division, Federal Institute for Drugs and Medical Devices, Bonn, Germany.
Abstract:
Real-world data are increasingly important for regulatory and health technology assessment decision-making, yet their effective use across Europe remains limited by technical, methodological, regulatory, and societal challenges. Drawing on the experiences of six Horizon Europe projects in the MetReal cluster, this review summarizes common barriers and emerging solutions for the use of real-world data in regulatory decision-making. Key challenges include complex and lengthy data access procedures, fragmented governance frameworks, variable data quality and completeness, limited interoperability, methodological difficulties in analyzing heterogeneous datasets, and infrastructure constraints within secure data environments. The article highlights opportunities to address these barriers through improved metadata, harmonization, federated analytics, synthetic data sandboxes, sustainable funding, and stronger collaboration between researchers, regulators, health technology assessment bodies, data holders, and citizens. These recommendations aim to strengthen Europe's health data ecosystem and support more robust, efficient, and trusted evidence generation for public health and patient benefit.
Related Concept Videos
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Therapeutic Drug Monitoring: Affecting Factors
Regression Toward the Mean
Clinical Trials
There are four phases in a clinical trial. A phase one...
Drug Control Governance: Regulatory Bodies and Their Impact